(Q36367268)

English

Antiviral prophylaxis in patients with haematological malignancies and solid tumours: Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Oncology (DGHO).

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16410361%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Antiviral prophylaxis in patients with haematological malignancies and solid tumours: Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Oncology (DGHO) (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16410361%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

0 references

Oliver A Cornely

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16410361%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

author name string

M Sandherr

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16410361%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

H Einsele

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16410361%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

H Hebart

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16410361%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

C Kahl

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16410361%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

W Kern

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16410361%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

M Kiehl

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16410361%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

G Massenkeil

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16410361%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

O Penack

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16410361%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

X Schiel

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16410361%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

S Schuettrumpf

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16410361%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

A J Ullmann

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16410361%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Infectious Diseases Working Party, German Society for Hematology and Oncology

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16410361%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

publication date

12 January 2006

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16410361%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16410361%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

17

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16410361%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16410361%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

1051-1059

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16410361%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Common community respiratory viruses in patients with cancer: more than just "common colds".

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ132

21 January 2018

Opportunistic infections after treatment with monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ132

21 January 2018

Quantitative Relationships Between Circulating Leukocytes and Infection in Patients with Acute Leukemia

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ132

21 January 2018

Oral acyclovir prophylaxis against herpes simplex virus in non-Hodgkin lymphoma and acute lymphoblastic leukaemia patients receiving remission induction chemotherapy. A randomised double blind, placebo controlled trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ132

21 January 2018

Acyclovir given as prophylaxis against oral ulcers in acute myeloid leukaemia: randomised, double blind, placebo controlled trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ132

21 January 2018

Acyclovir prophylaxis and fever during remission-induction therapy of patients with acute myeloid leukemia: a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ132

21 January 2018

Acyclovir prophylaxis against herpes simplex virus infection in patients with leukemia. A randomized, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ132

21 January 2018

Acyclovir prophylaxis of herpes-simplex-virus infections

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ132

21 January 2018

Oral acyclovir as prophylaxis for bacterial infections during induction therapy for acute leukaemia in adults. The Leukemia Group of Middle Sweden

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ132

21 January 2018

Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ132

21 January 2018

Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ132

21 January 2018

Prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with hemato-oncological neoplasias treated with chemotherapy

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ132

21 January 2018

Immunization recommendations for adults with cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ132

21 January 2018

Cancer patients undergoing chemotherapy show adequate serological response to vaccinations against influenza virus and Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ132

21 January 2018

Immunogenicity of vaccination against influenza, Streptococcus pneumoniae and Haemophilus influenzae type B in patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ132

21 January 2018

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ132

21 January 2018

Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ132

21 January 2018

Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ132

21 January 2018

Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ132

21 January 2018

Impact of therapy With chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: Intergroup Study Cancer and Leukemia Group B 9011.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ132

21 January 2018

Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ132

21 January 2018

Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL).

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ132

21 January 2018

Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission--experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG).

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ132

21 January 2018

Valacyclovir versus acyclovir for HSV prophylaxisin neutropenic patients

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ132

21 January 2018

Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ132

21 January 2018

Successful high-titer immunoglobulin therapy for persistent parvovirus B19 infection in a lymphoma patient treated with rituximab-combined chemotherapy.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ132

21 January 2018

Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximab

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ132

21 January 2018

Hepatitis B virus reactivation in a case of non-Hodgkin's lymphoma treated with chemotherapy and rituximab: necessity of prophylaxis for hepatitis B virus reactivation in rituximab therapy.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ132

21 January 2018

Infectious complications after autologous CD34-selected peripheral blood stem cell transplantation

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ132

21 January 2018

Infections in patients managed at home during autologous stem cell transplantation for lymphoma and multiple myeloma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ132

21 January 2018

Infectious complications after autologous peripheral blood progenitor cell transplantation followed by G-CSF.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ132

21 January 2018

Infectious complications after high-dose chemotherapy and autologous stem cell transplantation: comparison between patients with lymphoma or multiple myeloma and patients with solid tumors

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ132

21 January 2018

Infections during mobilizing chemotherapy and following autologous stem cell transplantation.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ132

21 January 2018

Hepatitis reactivation and liver failure in haemopoietic stem cell transplants for hepatitis B virus (HBV)/hepatitis C virus (HCV) positive recipients: a retrospective study by the Italian group for blood and marrow transplantation

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ132

21 January 2018

Hepatitis B reactivation in patients positive for hepatitis B surface antigen undergoing autologous hematopoietic cell transplantation

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ132

21 January 2018

Immune reconstitution following allogeneic peripheral blood stem cell transplants

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ132

21 January 2018

Cytokines, viruses, and graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ132

21 January 2018

Infection with Herpes Simplex Virus and Cell-Mediated Immunity after Marrow Transplant

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ132

21 January 2018

Long-term low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ132

21 January 2018

Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ132

21 January 2018

Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ132

21 January 2018

Transfusion-transmitted cytomegalovirus infection after receipt of leukoreduced blood products

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ132

21 January 2018

Prevention of cytomegalovirus disease in hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ132

21 January 2018

Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ132

21 January 2018

Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ132

21 January 2018

Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients. The Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ132

21 January 2018

Cidofovir for cytomegalovirus-preemptive therapy in stem cell transplant recipients

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ132

21 January 2018

Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ132

21 January 2018

Clinical strategies for the management of cytomegalovirus infection and disease in allogeneic bone marrow transplant

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ132

21 January 2018

Respiratory virus infections in transplant recipients after reduced-intensity conditioning with Campath-1H: high incidence but low mortality

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ132

21 January 2018

The role of hepatitis C and B virus infections as risk factors for severe liver complications following allogeneic BMT: a prospective study by the Infectious Disease Working Party of the European Blood and Marrow Transplantation Group

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ132

21 January 2018

Successful clearance of hepatitis B virus after allogeneic stem cell transplantation: beneficial combination of adoptive immunity transfer and lamivudine

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ132

21 January 2018

Lamivudine treatment for acute hepatitis B virus infection during allogeneic peripheral blood stem cell transplantation

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ132

21 January 2018

Effectiveness of prophylactic Anti-HBV therapy in allogeneic hematopoietic stem cell transplantation with HBsAg positive donors.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ132

21 January 2018

Hepatitis C virus infection and bone marrow transplantation: a cohort study with 10-year follow-up

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ132

21 January 2018

Infectious complications in 126 patients treated with high-dose chemotherapy and autologous peripheral blood stem cell transplantation

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDJ132

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36367268&oldid=1519146297"